SearchResearch
Beta
Hello! Describe your research question and I'll help you find matching datasets across 2,944 studies from AnVIL, BDC, CRDC, and KFDRC.

Contribution of Systemic and Somatic Factors to Clinical Response and Resistance in Urothelial Cancer

Request Access

Biomarkers (2)

  • Albumin less than 4 - Albumin less than 4 g/dL at treatment start (phv00405248.v1.p1)
  • Hb less than 10 - Hemoglobin less than 10 g/dL at treatment start (phv00405247.v1.p1)

Demographics (2)

Disease Events (16)

  • Alive Status - Alive at the time of final chart review (phv00405253.v1.p1)
  • Best OR - Best response per RECIST 1.1 (phv00405249.v1.p1)
  • IS_TUMOR - Tumor status (phv00405258.v1.p1)
  • Liver Mets - Liver metastases present at treatment start (phv00405244.v1.p1)
  • Ongoing Responder - Ongoing responder per RECIST 1.1 at the time of final chart review (phv00405250.v1.p1)
  • OS - Overall survival (phv00405254.v1.p1)
  • PD-L1 IC Score - The PD-L1 tumor-infiltrating immune cell (IC) status defined by the percentage of PD-L1 positive ICs in the tumor microenvironment by immunohistochemistry using the SP142 assay (Ventana, AZ, USA) (phv00405236.v1.p1)
  • Perioperative chemo_POD within 12 months - Previous perioperative chemotherapy, with first progression within 12 months (phv00405240.v1.p1)
  • PFS - Progression free survival per RECIST 1.1 (phv00405252.v1.p1)
  • PRIMARY_METASTATIC_TUMOR - Primary tumor or metastasis (phv00405259.v1.p1)
  • PRIMARY_TUMOR_LOCATION - Primary tumor location (phv00405261.v1.p1)
  • Prior BCG - History of prior intravesical BCG treatment (phv00405238.v1.p1)
  • Prior Lines - Number of previous systemic regimens in the metastatic setting (phv00405239.v1.p1)
  • Still on Treatment - Still on study therapy at the time of final chart review (phv00405251.v1.p1)
  • TFLC less than 3mo - Time from last chemotherapy less than 3 months (phv00405245.v1.p1)
  • Visceral Mets - Visceral metastases presents at treatment start (phv00405243.v1.p1)

Substance Use (1)

Other (16)